Shenyang Xingqi Pharmaceutical (300573.SZ) has obtained a drug registration certificate.

Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company has received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for the brimonidine tartrate eye drops. This product is a compound eye drop with brimonidine tartrate as the active ingredient. The brimonidine tartrate eye drops approved by the company this time are a multi-dose specification product, indicated for lowering intraocular pressure in patients with open-angle glaucoma and ocular hypertension. The efficacy of reducing intraocular pressure may gradually decrease in some patients with long-term use of this product. The time of decreased efficacy varies from person to person, so close monitoring should be provided.